Annals for Hospitalists Inpatient Notes - Intravenous Iron Supplementation for Patients With Heart Failure—What Hospitalists Should Know
Authors: Konrad Teodor Sawicki, Hossein Ardehali
Journal: Annals of Internal Medicine (2022)

Web ExclusivesApril 2022Annals for Hospitalists Inpatient Notes - Intravenous Iron Supplementation for Patients With Heart Failure—What Hospitalists Should KnowKonrad Teodor Sawicki, MD, PhD and Hossein Ardehali, MD, PhDKonrad Teodor Sawicki, MD, PhDFeinberg Cardiovascular Research Institute and Division of Cardiology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (K.T.S., H.A.). and Hossein Ardehali, MD, PhDFeinberg Cardiovascular Research Institute and Division of Cardiology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (K.T.S., H.A.).Author, Article, and Disclosure Informationhttps://doi.org/10.7326/M22-0637 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail A 58-year-old man with heart failure with reduced ejection fraction (HFrEF) due to ischemic heart disease presented with weight gain, shortness of breath, and dysuria over the past week. He was warm on examination, with lower extremity swelling and elevated jugular venous pressure. Laboratory results were notable for B-type natriuretic peptide level of 800 ng/L (baseline, 100 ng/L), creatinine level of 79.56 µmol/L (0.9 mg/dL), transferrin saturation of 15% (baseline, 25%), and ferritin level of 200 µg/L. Intravenous diuretics and antibiotics were initiated.Iron is essential for oxygen delivery and metabolic homeostasis. Despite advances in our understanding of iron metabolism, ...References1. Graham FJ, Masini G, Pellicori P, et al. Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure. Eur J Heart Fail. 2021. [PMID: 34050582] doi:10.1002/ejhf.2251 CrossrefMedlineGoogle Scholar2. Ponikowski P, Kirwan BA, Anker SD, et al; AFFIRM-AHF investigators. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet. 2020;396:1895-1904. [PMID: 33197395] doi:10.1016/S0140-6736(20)32339-4 CrossrefMedlineGoogle Scholar3. Jankowska EA, Kirwan BA, Kosiborod M, et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. Eur Heart J. 2021. [PMID: 34080008] doi:10.1093/eurheartj/ehab234 CrossrefMedlineGoogle Scholar4. Beverborg NG, Klip IT, Meijers WC, et al. Definition of iron deficiency based on the gold standard of bone marrow iron staining in heart failure patients. Circ Heart Fail. 2018;11:e004519. [PMID: 29382661] doi:10.1161/CIRCHEARTFAILURE.117.004519 CrossrefMedlineGoogle Scholar5. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137-e161. [PMID: 28455343] doi:10.1161/CIR.0000000000000509 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Feinberg Cardiovascular Research Institute and Division of Cardiology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (K.T.S., H.A.).Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M22-0637.Corresponding Author: Hossein Ardehali, MD, PhD, Northwestern University Feinberg School of Medicine, 303 East Superior Avenue, Chicago, IL 60611; e-mail, [email protected]. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoAnnals for Hospitalists - April 2022 Megan Mack , Matthew Luzum , and David H. Wesorick Metrics Cited byIron Metabolism in Cardiovascular Disease: Physiology, Mechanisms, and Therapeutic TargetsIron homeostasis in the heart: Molecular mechanisms and pharmacological implicationsFerric derisomaltose therapy and heart failure: implications and molecular insights April 2022Volume 175, Issue 4Page: HO2-HO3KeywordsCardiology and cardiovascular diseasesHeart failureIron deficiency ePublished: 19 April 2022 Issue Published: April 2022 Copyright & PermissionsCopyright © 2022 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...